Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Liquidia Corporation (LQDA)
A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- As much as 57% of Liquidia Corporation's (NASDAQ: LQDA) share value reportedly vanished after a court found that Yutrepia infringed two valid claims of United Therapeutics' '327 patent. If you bought LQDA and are now sitting on a loss, you have legal rights. Investors who suffered losses are encouraged to check whether you may qualify to recover your LQDA losses. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Seeking Alpha, GuruFocus, Stocktwits, and Yahoo Finance each tied the sell-off to the patent ruling. The court found two of the six asserted '327 patent claims valid and infringed. None of the four outlets identified an earnings miss or guidance cut as the catalyst. Levi & Korsinsky is investigating potential securities law violations on behalf of Liquidia investors who suffered losses in the decline.
The market was repricing a product that generated $300.3 million in sales in the first six months of 2026, according to Liquidia's August 12, 2026 Form 10-Q. The ruling raised remedy risk, including removal of Yutrepia's PH-ILD indication and broader restrictions on product availability. United Therapeutics has also sought an injunction. CEO Roger Jeffs said the Company disagreed with the decision and would pursue appellate options.
Shareholders who lost money in the LQDA sell-off may request a confidential review of their LQDA losses today or call (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the LQDA Investigation
Q: How much did LQDA stock drop? A: Shares fell approximately 57% after a court found that Yutrepia infringed two valid claims of United Therapeutics' '327 patent. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Liquidia Corporation made materially false or misleading statements regarding the status and potential consequences of United Therapeutics' patent litigation over Yutrepia. When the court's finding that Yutrepia infringed two valid claims of the '327 patent became public, the stock price declined sharply.
Q: What do LQDA investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my LQDA shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought LQDA and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
